Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY: CYBN )

9.530 +0.060 (+0.63%)
Official Closing Price Updated: 8:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
39 40 Next >
Psychedelic Stock Gainers And Losers From August 23, 2022
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 5.33% at $14.24 
Via Benzinga
Small Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 10.34% at $0.16 
Via Benzinga
FT-104: Field Trip’s Latest Psychedelic Drug Candidate
Via Investor Brand Network
Small Pharma, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 29.35% at $0.14 LOSERS: 
Via Benzinga
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
  
Via Benzinga
Why Bed Bath & Beyond Is Trading Lower By Over 40%, Here Are 55 Stocks Moving In Friday's Mid-Day Session
Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 145% to $38.45 on continued volatility following the company's IPO on Thursday. 
Via Benzinga
Study Suggests LSD May Boost Learning, Memory by Enhancing Neural Plasticity
Via Investor Brand Network
Psychedelic Stock Gainers And Losers From August 17, 2022
  
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Partner Receive Required Schedule I License from DEA for First-in-Human Clinical Trial
Via Investor Brand Network
BREAKING: Cybin And Clinilabs Receive DEA License For First-In-Human Clinical Trial Of Psilocybin To Treat Depression
Cybin Inc. (NEO: CYBN) (NYSE: CYBN) and Clinilabs Drug Development Corporation (Clinilabs) announced that the U.S. 
Via Benzinga
Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From August 16, 2022
  
Via Benzinga
These Depression Players Are Top Picks For $400B Mental Healthcare Market, Says Analyst
HC Wainwright expects COMPASS Pathways Plc (NASDAQ: CMPS) and Cybin Inc (NYSE: CYBN) to be leaders in the emerging $400 billion mental healthcare market. 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Results of Annual Meeting of Shareholders
Via Investor Brand Network
Cybin Announces Results of Shareholders’ Meeting
From Cybin Inc.
Via Business Wire
Allied, Cybin Among Top Psychedelic Movers Of Today
  
Via Benzinga
Major Psychedelic Stocks Down This Week; Still Up Since End Of June
The 8 stocks in our Psychedelic Compounds-Based Drug Stocks Index dropped 8.4% this week for the first time in 5 weeks but are still up 45.3% since then. 
Via Talk Markets
Mind Medicine, Numinus Wellness Among Top Psychedelic Movers From Today
  
Via Benzinga
Psilocybin Lawsuit Filed in Canada May Boost Global Psychedelics Reform Efforts
Via Investor Brand Network
Topics Lawsuit
Exposures Financial Legal
Compass Pathways, Revive Therapeutics Among Top Psychedelic Movers Of Today
  
Via Benzinga
Psychedelic Stock Gainers And Losers From August 10, 2022
  
Via Benzinga
Brain Fingerprinting Adolescents Could Predict Future Mental-Health Issues
Via Investor Brand Network
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – August 10, 2022 – Toronto’s Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study... 
Via FinancialNewsMedia
Topics Supply Chain
Exposures Supply Chain
3 Best Psychedelic Stocks to Buy Now
These are three of the best psychedelic stocks to buy to get in on the next generation of treatment for mental health disorders. 
Via InvestorPlace
This Psychedelics Company Is Setting Up An Equity Program For Up To $35M In Shares
Cybin Inc. (NEO: CYBN) (NYSE: CYBN) has launched an at-the-market (ATM) equity program through which it will issue and sell up to $35 million in common shares in the company’s capital, from the... 
Via Benzinga
Cybin, Field Trip Health Among Top Psychedelic Movers Of Today
  
Via Benzinga
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Unveils Equity Program, Releases Q1 Financial Report
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program
From Cybin Inc.
Via Business Wire
Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Toronto Firm Receives First Federal Government Funding to Study Psilocybin
Via Investor Brand Network
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.